Equities Analysts Offer Predictions for Insmed Q3 Earnings

Insmed, Inc. (NASDAQ:INSM) – Equities researchers at HC Wainwright increased their Q3 2025 earnings per share (EPS) estimates for Insmed in a research report issued on Wednesday, August 13th. HC Wainwright analyst A. Fein now anticipates that the biopharmaceutical company will post earnings per share of ($1.34) for the quarter, up from their prior forecast of ($1.35). HC Wainwright currently has a “Buy” rating and a $120.00 target price on the stock. The consensus estimate for Insmed’s current full-year earnings is ($4.56) per share. HC Wainwright also issued estimates for Insmed’s Q4 2025 earnings at ($1.16) EPS, FY2025 earnings at ($5.61) EPS, FY2026 earnings at ($2.37) EPS, FY2027 earnings at $0.74 EPS, FY2028 earnings at $4.35 EPS and FY2029 earnings at $8.99 EPS.

Insmed (NASDAQ:INSM) last announced its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported ($1.70) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.30) by ($0.40). Insmed had a negative net margin of 259.82% and a negative return on equity of 195.37%. The firm had revenue of $107.42 million during the quarter, compared to analysts’ expectations of $104.06 million. During the same quarter in the prior year, the business earned ($1.94) EPS. The company’s quarterly revenue was up 18.9% compared to the same quarter last year.

A number of other analysts have also commented on the company. UBS Group reaffirmed a “buy” rating and set a $133.00 price objective (up previously from $124.00) on shares of Insmed in a research note on Friday, August 8th. Royal Bank Of Canada reissued an “outperform” rating and issued a $120.00 price target (up from $108.00) on shares of Insmed in a research note on Friday, August 8th. Stifel Nicolaus raised their price target on Insmed from $121.00 to $145.00 and gave the stock a “buy” rating in a research note on Thursday. Morgan Stanley reaffirmed an “equal weight” rating and issued a $126.00 price objective on shares of Insmed in a research note on Wednesday. Finally, Truist Financial lifted their price objective on Insmed from $126.00 to $139.00 and gave the company a “buy” rating in a research note on Thursday. One research analyst has rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. According to MarketBeat.com, Insmed presently has a consensus rating of “Moderate Buy” and an average target price of $129.57.

Insmed Trading Up 0.0%

Shares of INSM stock opened at $127.80 on Friday. Insmed has a fifty-two week low of $60.40 and a fifty-two week high of $128.48. The stock has a market cap of $27.01 billion, a P/E ratio of -22.38 and a beta of 0.95. The business has a fifty day simple moving average of $103.62 and a 200-day simple moving average of $83.88. The company has a quick ratio of 6.33, a current ratio of 6.68 and a debt-to-equity ratio of 0.45.

Insider Buying and Selling

In related news, CFO Sara Bonstein sold 58,400 shares of the company’s stock in a transaction on Monday, July 21st. The stock was sold at an average price of $102.67, for a total transaction of $5,995,928.00. Following the completion of the transaction, the chief financial officer directly owned 73,505 shares in the company, valued at $7,546,758.35. This represents a 44.27% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Orlov S. Nicole Schaeffer sold 99,172 shares of the company’s stock in a transaction on Wednesday, June 11th. The stock was sold at an average price of $93.42, for a total value of $9,264,648.24. Following the transaction, the insider owned 89,407 shares of the company’s stock, valued at approximately $8,352,401.94. The trade was a 52.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 525,716 shares of company stock worth $49,665,671 in the last three months. 3.00% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its position in Insmed by 0.3% during the 1st quarter. Vanguard Group Inc. now owns 18,268,122 shares of the biopharmaceutical company’s stock worth $1,393,675,000 after acquiring an additional 49,149 shares during the period. Darwin Global Management Ltd. boosted its position in Insmed by 23.5% during the 4th quarter. Darwin Global Management Ltd. now owns 12,960,538 shares of the biopharmaceutical company’s stock worth $894,796,000 after acquiring an additional 2,463,261 shares during the period. Price T Rowe Associates Inc. MD boosted its position in Insmed by 1.7% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 12,923,541 shares of the biopharmaceutical company’s stock worth $985,938,000 after acquiring an additional 219,131 shares during the period. Capital International Investors boosted its position in Insmed by 9.1% during the 4th quarter. Capital International Investors now owns 7,116,997 shares of the biopharmaceutical company’s stock worth $491,357,000 after acquiring an additional 593,206 shares during the period. Finally, Adage Capital Partners GP L.L.C. boosted its position in Insmed by 109.2% during the 1st quarter. Adage Capital Partners GP L.L.C. now owns 3,446,944 shares of the biopharmaceutical company’s stock worth $262,967,000 after acquiring an additional 1,799,382 shares during the period.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.